Impacts of Pretransplant Comorbidities on Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 149-153

  Sorror, Mohammed ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DISEASE FREE SURVIVAL; HUMAN; KARNOFSKY PERFORMANCE STATUS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 64749099075     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.12.498     Document Type: Article

References (11)

1. van Spronsen D.J., Janssen-Heijnen M.L., Lemmens V.E., Peters W.G., and Coebergh J.W. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 41 (2005) 1051-1057
2. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40 (1987) 373-383
3. Extermann M. Measuring comorbidity in older cancer patients. (Review). Eur J Cancer 36 (2000) 453-471
4. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 104 (2004) 961-968
5. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood 104 (2004) 1550-1558
6. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
7. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25 (2007) 4246-4254
8. Sorror M.L., Storer B.E., Maloney D.G., Sandmaier B.M., Martin P.J., and Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111 (2008) 446-452
9. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 110 (2007) 4608-4613
10. Sorror M., Storer B., Sandmaier B.M., et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112 (2008) 1992-2001
11. Sorror M., Storer B., Gopal A., et al. Comorbidity, lactate dehydrogenase (LDH), and chemosensitivity are independent predictors of mortality after autologous hematopoietic cell transplantation (HCT) for patients (pts) with lymphoma. Blood 110 Part 1 (2007) 190a, #616(Abstract)